about us

About us

Kedrion Biopharma is an international biopharmaceutical company based in Italy that collects and fractionates plasma to produce and distribute worldwide plasma-derived products for the prevention and treatment of rare and debilitating diseases and conditions such as Hemophilia, Primary Immunodeficiencies and Rh sensitization.

Kedrion operates in Germany through its subsidiary Kedrion Biopharma GmbH offering a portfolio of medicines and licensed products to treat Immunology and Intensive care and Transplantation patients.

 


Read more

PRODUCT PORTFOLIO

As a result of its solid and successful experience as partner with the Italian Health System, its significant expansion into international operations and a fundamental commitment to research and development, Kedrion’s line of plasma-derived products is broad and diverse.

With treatments for many rare and debilitating diseases and conditions from hemolytic disease in newborns to immune deficiencies to hemophilia, Kedrion offers a wide and expanding array of treatments and therapies.

 


RARE DISEASES

INTENSIVE CARE & TRANSPLANTATION

Therapeutic Areas

Our continuing commitment to research, development and innovation aims to meet the therapeutic needs of the largest number of patients living with a rare disease or debilitating condition across the world.

Below the list of Kedrion products distributed in Germany (updated March 2022).



Rare Diseases
Rare Diseases
This Area focuses on diseases such as Hemophilia, Von Willebrand Disease, Immune System Disorders and Neurology.
CONTINUE READING
mother-and-child
Mother and Child Health
This Area focuses on Hemolytic Disease of the Fetus and Newborn and on vertical (mother to child) transmission of Hepatitis B.
CONTINUE READING
Intensive Care
Intensive Care and Transplantation
This Area focuses on Hepatitis B, Human Albumin, Antithrombin, Prothrombin Complex Coagulation Factors (PCC) and Rabies.
CONTINUE READING
Trasfusional Medicine
TRANSFUSION MEDICINE
This Area focuses on Plasma S/D and Pathogen Safety.
CONTINUE READING

News

01/09/2022
Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
CONTINUE READING
21/10/2021
Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
CONTINUE READING
30/06/2021
Kedrion stronger in North America and further committed to rare diseases
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
CONTINUE READING

Download area

Download the files



View documents
download area


Contact us

Thank you for your interest in Kedrion. You can contact us directly by submitting a message form. Please follow the links below according to your interests or subject of inquiry.



MARKETING & GENERAL INQUIRIES
For commercial information

EN: Kedrion In The World
Policy *
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MEDICAL INFORMATION
For medical information regarding our products

EN: Medical scientific information
Qualification *
If medical, please indicate your specialty
If patient, please report the contact details of the doctor or the treating center
Please do not use this field to report adverse events (side effects) or product complaints: In the event of a complaint, please contact the Quality Assurance department. In case of adverse reactions please contact the Pharmacovigilance.
Privacy Policy *
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHARMACOVIGILANCE
To report an adverse reaction to one of our products.
Contact the Competent Authority’s Pharmacovigilance Office.
If you wish to directly notify Kedrion about a suspected adverse reaction related to our drugs, please fill in the form below:

EN: Pharmacovigilance
Qualification *
Gender (M/F)
Has the adverse event stopped?
How bad was the adverse event?
How is the adverse event now?
In processing your personal data, Kedrion will fully comply with internationally recognized standards of data protection. In doing so, Kedrion ensures compliance of its staff with strict standards of security and confidentiality.
Privacy *
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.